CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$31.49
0.01 (0.03%)
▲
5d:
+0.0%
30d:
+0.38%
90d:
+24.27%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 3.5/10
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CPRX shows positive signals but monitor for confirmation. Market pricing in 2.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CPRX shows positive signals but monitor for confirmation. Market pricing in 2.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$53.03
Based on 13.1% avg growth
INTRINSIC VALUE TODAY
$32.92
4.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $31.49, which is considered slightly high relative to its 30-day fair value range of $31.44 to $31.49. The stock's valuation (Forward PE: 9.9) is in line with its historical norms (9.1). At these levels, the market is pricing in 2.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$31.44 -
$31.49
Company Quality Score
59/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- BULLISH: Options cheap (IV 23th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($31.67)
- NEUTRAL: Market pricing in 2.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$31.44 -
$31.49
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.64
(5.2%)
Support & Resistance Levels
Support Level
$31.43
Resistance Level
$31.51
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.90
Wall Street Target
$31.67
(+0.6%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
11.1%
Profit Margin
37.1%
Valuation Premium vs History
+2.9% premium
PE vs Historical
9.9 vs 9.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$32.40
(+3%)
2-Year Target
$33.34
(+6%)
3-Year Target
$34.31
(+9%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$31.54
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.1%)
$69.74
(+122%)
Base:
(SPY PE: 9.9, Growth: 22.1%)
$31.70
(+1%)
Bear:
(PE: 8.4, Growth: 22.1%)
$26.94
(-14%)
Share & Embed Analysis
Last updated: August 02, 2026 9:48 PM ET
Data refreshes hourly during market hours. Next update: 10:48 PM
Data refreshes hourly during market hours. Next update: 10:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
